These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36209375)

  • 1. Sweet syndrome after the first dose of SARS-CoV-2 vaccine (Pfizer-BioNTech).
    Kim MJ; Kim JW; Na JI
    Dermatol Ther; 2022 Dec; 35(12):e15915. PubMed ID: 36209375
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine.
    Darrigade AS; Théophile H; Sanchez-Pena P; Milpied B; Colbert M; Pedeboscq S; Pistone T; Jullié ML; Seneschal J
    Allergy; 2021 Oct; 76(10):3194-3196. PubMed ID: 34143448
    [No Abstract]   [Full Text] [Related]  

  • 4. SARS-CoV-2 vaccine induced Sweet syndrome : a case report.
    Ben Rejeb S; Beltaifa D; Dhaoui A; Derbel F; Bellil K
    Tunis Med; 2021 Décembre; 99(12):1188-1191. PubMed ID: 35288926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: A case report.
    Capassoni M; Ketabchi S; Cassisa A; Caramelli R; Molinu AA; Galluccio F; Guiducci S
    J Med Virol; 2021 Oct; 93(10):5718-5720. PubMed ID: 34214206
    [No Abstract]   [Full Text] [Related]  

  • 6. Sweet Syndrome following SARS-CoV-2 CoronaVac vaccine.
    Ben Salah N; Korbi M; Ben Fadhel N; Safa I; Chad F; Njima M; Belhadjali H; Amri M; Aouam K; Zili J
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):e873-e875. PubMed ID: 35723896
    [No Abstract]   [Full Text] [Related]  

  • 7. Atypical presentation of Sweet syndrome with nodular erythema and oral ulcerations provoked by Ad26.COV2.S SARS-CoV-2 vaccination and review of literature.
    Bechtold A; Owczarczyk-Saczonek A
    Dermatol Ther; 2022 Dec; 35(12):e15923. PubMed ID: 36219526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sweet syndrome after severe acute respiratory syndrome coronavirus 2 mRNA vaccine: A case report and literature review.
    Hoshina D; Orita A
    J Dermatol; 2022 May; 49(5):e175-e176. PubMed ID: 35037288
    [No Abstract]   [Full Text] [Related]  

  • 9. Pityriasis lichenoides chronica after BNT162b2 Pfizer-BioNTech vaccine: A novel cutaneous reaction after SARS-CoV-2 vaccine.
    Drago F; Ciccarese G; Guadagno A; Parodi A
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e979-e981. PubMed ID: 35841285
    [No Abstract]   [Full Text] [Related]  

  • 10. Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine.
    Žagar T; Hlača N; Brajac I; Prpić-Massari L; Peternel S; Kaštelan M
    Br J Dermatol; 2022 Mar; 186(3):e110. PubMed ID: 34817862
    [No Abstract]   [Full Text] [Related]  

  • 11. Nephrotic syndrome with minimal change disease after the Pfizer-BioNTech COVID-19 vaccine: two cases.
    Hartley JL; Bailey N; Sharma A; Shawki H
    BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35246429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
    Eyre DW; Lumley SF; Wei J; Cox S; James T; Justice A; Jesuthasan G; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Jones EY; Stuart DI; Ebner D; Hoosdally S; Crook DW; Peto TEA; Walker TM; Stoesser NE; Matthews PC; Pouwels KB; Walker AS; Jeffery K
    Clin Microbiol Infect; 2021 Oct; 27(10):1516.e7-1516.e14. PubMed ID: 34111577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine.
    Jedlowski PM; Jedlowski MF
    Dermatol Online J; 2021 Jan; 27(1):. PubMed ID: 33560802
    [No Abstract]   [Full Text] [Related]  

  • 15. Delayed-type hypersensitivity reactions to Pfizer BioNTech SARS-CoV-2 vaccine.
    Beyaz Ş; Öksüzer Çimşir D; Çelebi Sözener Z; Soyyiğit Ş; Öner Erkekol F
    Postgrad Med J; 2022 Sep; 98(1163):658-659. PubMed ID: 37062977
    [No Abstract]   [Full Text] [Related]  

  • 16. Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon.
    Powell J; Piszczatoski CR
    Ann Pharmacother; 2022 Sep; 56(9):1058-1064. PubMed ID: 35012364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female.
    Majid I; Mearaj S
    Dermatol Ther; 2021 Nov; 34(6):e15146. PubMed ID: 34590397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty
    Ando M; Satonaga Y; Takaki R; Yabe M; Kan T; Omote E; Yamasaki T; Komiya K; Hiramatsu K
    Int J Infect Dis; 2022 Nov; 124():187-189. PubMed ID: 36122668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020.
    Shimabukuro T
    Am J Transplant; 2021 Mar; 21(3):1332-1337. PubMed ID: 33641264
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.